Crocin Monotherapy in Non-Central Diabetic Macular Edema
-
Mojtaba Mojtahedzadeh
,
Masoud Reza Manaviat
,
Seyed Reza Mirjalili
,
Adeleh Sahebnasagh
,
Mohammad Khan Ardani
,
Farahnaz Hoseinzadeh
,
Fatemeh Saghafi
Abstract
Background: Crocin can be utilized as an anti-inflammatory component of Saffron in diabetic macular edema (DME), which is known as the most common cause of vision loss in patients with diabetes mellitus (DM). Although anti-vascular endothelial growth factor (VEGF) agents are common in non-center involving DME (NCI-DME), there is no consensus on NCI-DME treatment.
Methods: This before-after study was performed from October 2019 to August 2021. Twenty-six eyes of 16 patients with type 2 DM in Baghayipoor Clinic in Yazd, were treated with 15 mg crocin per day for 90 days. Patients had at least one eye with non-proliferative DR (NPDR) and NCI-DME along with no adherence to intravitreal injection or a contraindication of intravitreal injection. Central subfield thickness (CST), visual acuity, fasting blood sugar (FBS), and HbA1c were assessed once before and once after the study (day 90).
Results: After 90 days of therapy, the mean CST significantly decreased to 2.8 μm (P-value=0.030), four patients had increased CST and 1 patient had a significantly decreased CST (≥25μm). The mean Logarithmic Minimum angle of resolution increased during the study. The Mean (±SD) FBS showed a significant improvement during the study from 174.7 (±60.41) at baseline up to 161.8 (±47.7) at day 90 (P-value = 0.012). HbA1c had no significant reduction. Nausea/vomiting and insomnia were among the reported adverse effects. Nevertheless, no one withdrew from the study because of the adverse effects.
Conclusion: This study suggests Crocin’s positive impact on NCI-DME. It may also improve the glycemic profile of diabetic patients; however, more high-quality randomized clinical trials with larger sample sizes and longer durations are needed for validation.
2. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.
3. Heng L, Comyn O, Peto T, et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabetic Med. 2013;30(6):640-50.
4. Brown DM, Wykoff CC, Boyer D, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial. JAMA ophthalmo. 2021;139(9):946-55.
5. Chalakkal R, Hafiz F, Abdulla W, Swain A. An efficient framework for automated screening of Clinically Significant Macular Edema. Comput Biol Med. 2021;130:104128.
6. Kulkarni AD, Ip MS. Diabetic macular edema: therapeutic options. Diabetes Ther. 2012;3(1):1-14.
7. Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20-68.
8. Sepahi S, Mohajeri SA, Hosseini SM, et al. Effects of crocin on diabetic maculopathy: a placebo-controlled randomized clinical trial. Am J Ophthalmol. 2018;190:89-98.
9. Lin W, Feng M, Liu T, et al. Microvascular Changes After Conbercept Intravitreal Injection of PDR With or Without Center-Involved Diabetic Macular Edema Analyzed by OCTA. Front Med (Lausanne). 2022;9: 797087.
10. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center involved clinically significant diabetic macular edema. Retina. 2009;29(5):613-7.
11. Marashi A. Non-central diabetic clinical significant macular edema treatment with 532nm sub threshold laser. advances in ophthalmology & visual system. 2018;8(3):151-4.
12. Maturi RK, Glassman AR, Josic K, et al. Effect of intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the Protocol W Randomized Clinical Trial. JAMA ophthalmol. 2021;139(7):701-12.
13. Chiosi F, Rinaldi M, Campagna G, et al. Effect of a Fixed Combination of Curcumin, Artemisia, Bromelain, and Black Pepper Oral Administration on Optical Coherence Tomography Angiography Indices in Patients with Diabetic Macular Edema. Nutrients. 2022;14(7):1520.
14. Ahmed S, Hasan MM, Heydari M, et al. Therapeutic potentials of crocin in medication of neurological disorders. Food and Chem Toxicol. 2020;145:111739.
15. Rahmani J, Bazmi E, Clark C, Nazari SSH. The effect of Saffron supplementation on waist circumference, HA1C, and glucose metabolism: A systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2020;49:102298.
16. Giannoulaki P, Kotzakioulafi E, Chourdakis M, Hatzitolios A, Didangelos T. Impact of Crocus sativus L. on metabolic profile in patients with diabetes mellitus or metabolic syndrome: A systematic review. Nutrients. 2020;12(5):1424.
17. Taherifard MH, Shekari M, Mesrkanlou HA, et al. The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials. Complement Ther Med. 2020;52:102500.
18. Panozzo G, Cicinelli MV, Augustin AJ, et al. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification. Eur J Ophthalmol. 2020;30(1):8-18.
19. Tan X, Patel I, Chang J. Review of the four item Morisky medication adherence scale (MMAS-4) and eight item Morisky medication adherence scale (MMAS-8). INNOVATIONS in pharmacy. 2014;5(3):165.
20. Abou-Hany HO, Atef H, Said E, Elkashef HA, Salem HA. Crocin mediated amelioration of oxidative burden and inflammatory cascade suppresses diabetic nephropathy progression in diabetic rats. Chem Biol Interact. 2018;284:90-100.
21. Veritti D, Sarao V, Soppelsa V, Lanzetta P. Managing diabetic macular edema in clinical practice: systematic review and meta-analysis of current strategies and treatment options. Clin Ophthalmol. 2021;15:375-85.
22. Cuervo-Lozano E, González-Cortés JH, Olvera-Barrios A, et al. Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema. Int J Ophthalmol. 2018;11(6):981-5.
23. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-9.
24. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
25. Heier JS, Korobelnik J-F, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-85.
26. Mohan S, Chawla G, Surya J, Raman R. Intravitreal anti-vascular endothelial growth factor with and without topical non-steroidal anti-inflammatory in centre-involving diabetic macular edema. Indian J Ophthalmol. 2021;69(11):3279-82.
27. Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser‐Bell S. Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema. Cochrane Database Syst Rev. 2018;4(4):CD011599.
28. Ghasemi Falavarjani K, Nguyen Q. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787-94.
29. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database of Syst Rev. 2012;12:CD007419.
| Files | ||
| Issue | Vol 12, No 4 (Autumn 2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/jpc.v12i4.17451 | |
| Keywords | ||
| Diabetic Retinopathy Macular Edema Crocin Visual Acuity | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
